Full Press Release Details
Announces Update on SADA Technology
York, NY, May 13, 2021 (GLOBE NEWSWIRE) - Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs")
(Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD,
Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center ("MSK") will present a research update
on the Company's SADA technology platform at PEGS Boston Virtual Conference on May 13, 2021 at 1:20 p.m. Eastern Time.
The SADA technology was licensed by the Company from MSK and the Massachusetts Institute of Technology ("MIT").
presentation will focus on cancer therapeutics failing in development because of dose-limiting toxicities or subtherapeutic dosing as
a consequence of insufficient therapeutic index ("TI"). The two step SADA technology uses unique pharmacokinetics to potentially
improve the TI. When applied to pre-targeted radioimmunotherapy ("PRIT"), the bispecific SADA antibodies visualize tumors
with high precision using PET (diagnostic approach) and has been shown to ablate aggressive solid tumors using both beta and alpha emitters
such as 177Lu or 225Ac (therapeutic approach), potentially without significant toxicity to bone marrow, liver, kidney, or CNS. Furthermore,
the modularity of the SADA platform might allow easy adaptation to different tumor targets and a variety of payloads.
MSK, including Dr. Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs.
Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement,
MSK has institutional financial interests in the technology and Y-mAbs.
Y-mAbs is a late-stage
clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for
the treatment of cancer. The Company has a broad and advanced product pipeline, including including one FDA approved product, DANYELZA
(naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that
in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform
Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization
and product distribution plans; current and future clinical and pre-clinical studies and our research and development programs; expectations
related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals;
rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees;
our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional
product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related
to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance,
including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and
our industry; and other statements that are not historical facts. Words such as anticipate,'' believe,''
"contemplate," continue,'' could,'' estimate,''
expect,'' "hope," intend,'' may,'' might,''
plan,'' potential,'' predict,'' project,''
should,'' target,'' "will", would'' and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including
but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development
work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory
submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product
including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and
risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties
including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government
regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to
employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the coronavirus
known as COVID-19 and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section
included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC and in our other SEC filings.
Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation
to update any forward-looking statement, whether as a result of new information, future events or otherwise.
and "Y-mAbs" are registered trademarks of Y-mAbs Therapeutics, Inc.